The p53 pathway
Carol L. Prives, Peter A. Hall · The Journal of Pathology · 1999
Abnormalities of the p53 tumour suppressor gene are among the most frequent molecular events in human and animal neoplasia. Moreover, p53 is one of the most studied proteins in the whole of contemporary biology, with more than 12,500 papers so far written! In this review the choice has been deliberately made not to be fully comprehensive in the coverage of the huge p53 literature. Rather attention is focused on a small number of recent developments which are reviewed in the context of modern models of p53 function. Progress in the analysis of signalling to p53 including phosphorylation cascades, and interactions with proteins such as mdm2 and ARF are highlighted. The plethora of protein-protein interactions is discussed, as are the strategies for defining downstream targets of p53. Finally, the emerging biology of p53 homologues is considered. The need for bridging the gap between reductionist, biochemical and biophysical studies and biological and genetic analysis is emphasized. Only this will provide the needed framework for utilizing the information in clinical care.
Cited by 1,307 works. doi:10.1002/(sici)1096-9896(199901)187:1<112::aid-path250>3.0.co;2-3 Open-access PDF
Authors
References
- T antigen is bound to a host protein in SY40-transformed cells
- p53, the Cellular Gatekeeper for Growth and Division
- Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells
- The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
- Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
- Mdm2 promotes the rapid degradation of p53
- p53: puzzle and paradigm.
- Definition of a consensus binding site for p53
- Regulation of p53 stability by Mdm2
- Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain